Header

UZH-Logo

Maintenance Infos

Browse by Creators

Navigate back| Up a level
Export as
Number of items: 5.

Barthelmes, D; Walton, R; Campain, A E; Simpson, J M; Arnold, J J; McAllister, I L; Guymer, R H; Hunyor, R H; Essex, R W; Morlet, N; Gillies, M C (2015). Outcomes of persistently active neovascular age-related macular degeneration treated with VEGF inhibitors: observational study data. The British Journal of Ophthalmology, 99(3):359-364.

Gillies, M C; Campain, A; Walton, R; Simpson, J M; Arnold, J J; Guymer, R H; McAllister, I L; Hunyor, A P; Essex, R W; Morlet, N; Barthelmes, D (2015). Time to initial clinician-reported inactivation of neovascular age-related macular degeneration treated primarily with ranibizumab. Ophthalmology, 122(3):589-594.e1.

Gillies, M C; Walton, R; Liong, J; Arnold, J J; McAllister, I; Morlet, N; Hunyor, A; Guymer, R; Keeffe, J; Essex, R; Herrera-Bond, A; Glastonbury, B; Simpson, J M; Barthelmes, D (2014). Efficient capture of high-quality data on outcomes of treatment for macular diseases: The Fight Retinal Blindness! Project. Retina, 34(1):188-195.

O'Day, R; Walton, R; Blennerhassett, R; Gillies, M C; Barthelmes, D (2014). Reporting of harms by randomised controlled trials in ophthalmology. The British Journal of Ophthalmology, 98(8):1003-1008.

Gillies, M C; Walton, R; Simpson, J M; Arnold, J; Guymer, R H; McAllister, I L; Hunyor, A P; Essex, R W; Morlet, N; Barthelmes, D (2013). Prospective audit of exudative age-related macular degeneration: 12-month outcomes in treatment-naive eyes. Investigative Ophthalmology & Visual Science [IOVS], 54(8):5754-5760.

This list was generated on Sun May 26 00:57:01 2019 CEST.